Elevated plasma S100A1 level is a risk factor for ST-segment elevation myocardial infarction and associated with...

Area of Science:

• Cardiology
• Biomarker Research
• Acute Coronary Syndromes

Background:

• ST-segment elevation myocardial infarction (STEMI) is a critical cardiovascular event.
• Identifying reliable biomarkers for STEMI prediction and prognosis is crucial for patient management.

Purpose of the Study:

• To investigate the association between plasma S100A1 levels and STEMI.
• To assess the potential role of S100A1 in predicting cardiac function after myocardial infarction.

Main Methods:

• Plasma S100A1 levels were measured in 207 STEMI patients and 217 healthy controls.
• Correlation analysis was used to examine relationships with other cardiac biomarkers.
• Multivariate logistic regression assessed the predictive value of S100A1 for STEMI occurrence and cardiac function.

Main Results:

• STEMI patients exhibited significantly higher plasma S100A1 levels compared to controls (P<0.001).
• S100A1 showed significant correlations with hs-cTnT, CK-MB, LVEF, NT-proBNP, and hs-CRP.
• Elevated S100A1 (> 1965.9 pg/mL) was an independent predictor of STEMI (OR: 6.925) and associated with poorer cardiac function.

Conclusions:

• Elevated plasma S100A1 is a significant predictor of STEMI.
• S100A1 may serve as a valuable biomarker reflecting cardiac function post-acute coronary ischemia.